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INTRODUCTION 
Alzheimer’s disease is a fatal neurodegenerative disorder originally characterized by three 
neuropathological features including intracellular neurofibrillary tangles (NFTs) consisting of 
hyperphosphorylated tau protein1, senile plaques formed by aggregated amyloid β peptides 
(Aβ)2 and lipid granule accumulations (lipoid granules) in neuroglia.3,4 According to the amyloid 
hypothesis2, accumulation of Aβ is the primary influence triggering AD pathogenesis and the 
rest of the disease process.5 Aβ aggregates into oligomers, which can be of various sizes, and 
forms diffuse and neuritic plaques in the brain parenchyma, leading to loss of synapses and 
neurons.6,7 However, molecular mechanisms of how monomeric Aβ peptides are converted to 
neurotoxic oligomers and further to fibrils rich in cross β-sheet motifs are indeterminate.  
Alois Alzheimer’s originally reported  pathologic hallmark of AD; lipoid granules in neuroglia4 
and strong clinical evidence demonstrated in the ensuing years suggest an aberrant lipid 
homeostasis associated with AD pathology along with peptide and protein centric 
mechanisms, in part for the following reasons.3,8 All APP-cleaving secretases as well as APP 
are transmembrane proteins, suggesting a direct relationship of amyloid pathology with 
neuronal membrane lipids. Importantly, growing evidence indicates that amyloidogenic 
processing of APP occurs in lipid rafts, largely because functionally active pools of BACE1 and 
γ-secretase are present in these cholesterol- and sphingolipid rich membrane micro domains.9 
It is also known that Aβ exerts its cytotoxic effects, at least partly, by perturbating cellular 
membranes, potentially through the modulation of the activity of phospholipases, such as 
PLA210 and PLC.11 On the other hand, lipid species, such as ganglioside GM1 was found to 
trigger Aβ aggregation.12 Indeed, a major risk factor for sporadic AD (SAD) is the ε4 allelic 
variant of the apolipoprotein E (APOE) gene, which encodes a protein in cholesterol 
metabolism and lipid transport further linking AD pathology to lipids13. It is thus clear that there 
is an interrelating molecular pathology of neuronal lipids, peptides and proteins associated with 
AD pathology.8,14,15 Therefore, a comprehensive lipidome and peptidome/proteome analysis 
would provide a basis for further understanding of associated molecular changes in AD 
pathogenesis. 
Advances in lipidomics and peptidomics/proteomics, particularly through the use of 
electrospray ionization mass spectrometry (ESI-MS), has facilitated an accurate profiling of 
AD-associated changes in lipids such as cholesterol16, plasmalogens17, sphingolipids18, 
amyloid peptides19 and protein species such as apoE4 protein20 in brain tissue. However, these 
studies were performed using brain tissue extracts where spatially confined changes are 
convoluted, restricting the direct correlation of molecular information with amyloid plaques 
which are scenes of AD pathogenesis. Therefore, advanced chemical imaging techniques are 
required to characterize disease pathology in situ, such as imaging mass spectrometry (IMS).21 
This technique is suited to probe amyloid plaque-associated molecular pathology in specific 
brain regions.22-31 In particular, MALDI-IMS was shown to be a powerful technique to probe 
amyloid plaque-associated Aβ isoforms and neuronal lipids in transgenic mice and post-
mortem human AD brains.23,27-31  
Although the vast majority of AD cases are classified as late-onset SAD, rare  but highly 
penetrant autosomal mutations in genes encoding APP and presenilin 1 and presenilin 2, the 
catalytic components of the γ-secretase, result in early-onset familial AD (FAD)32, sharing 
certain pathological characteristics with SAD. Therefore, transgenic animal models of AD can 
serve as model systems for more thorough investigations of the aggregation mechanisms, cell 
signaling and metabolic pathways in vivo. For example, the mouse model (tgArcSwe), carrying 
both the Arctic (E693G) and the Swedish (K670M/N671L) mutation, displays extensive Aβ 
deposition with an early onset age of 5–6 months33, and is therefore a well-suited model system 
to study Aβ plaque pathology.   
In this communication, we attempted to shed a light on the molecular pathology of individual 
hippocampal Aβ plaques in 18 month-old tgArcSwe mice, which can give insight into the 
pathophysiological processes leading to disease states in AD. We utilized multimodal MALDI-
IMS analysis on the same tissue sections to sketch a high-throughput molecular architecture 
of individual amyloid plaques. Subsequent high-spatial resolution (10μm) dual polarity lipid and 
peptide/protein MALDI-IMS analysis on the same regions of single tissue sections allowed 
correlation of the ion images of lipids including sphingolipids, phospholipids, lysophospholipids 
with multiple amyloid β isoforms at cellular levels in specific brain regions such as hippocampus 
of tgArcSwe, where extensive amyloid plaque accumulations were observed. 
EXPERIMENTAL SECTION 
METHODS 
Chemicals and Reagents. All chemicals for matrix and solvent preparation were pro-analysis 
grade and obtained from Sigma-Aldrich (St. Louis, MO), unless otherwise specified. 
TissueTek optimal cutting temperature (OCT) compound was purchased from Sakura Finetek 
(AJ Alphen aan den Rijn, the Netherlands). The ddH2O was obtained from a MilliQ purification 
system (Merck Millipore, Darmstadt, Germany). 
Animals, Tissue Sampling and Sectioning. Transgenic mice (n = 3), 18 months of age, with 
the Arctic (E693G) and Swedish (K670N, M671L) mutations (tgArcSwe) of human APP were 
reared ad libitum at the animal facility at Uppsala University under a 12/12-hlight/dark cycle. 
The animals were anesthetized with isoﬂurane and killed by decapitation. The brains were 
dissected quickly with 3 min postmortem delay and frozen on dry ice. All animal procedures 
were approved by an ethical committee and performed in compliance with national and local 
animal care and use guidelines (DNr #C17⁄ 14 at Uppsala University). Frozen tissue sections 
(12 µm thick) were cut in a cryostat microtome (Leica CM 1520, Leica Biosystems, Nussloch, 
Germany) at -18°C, and collected on special-coated, conducting glass slides (indium tin oxide, 
Bruker Daltonics, Bremen, Germany) and stored at -80°C.  
 
Sample Preparation and Matrix Application Strategies. Prior to matrix deposition by 
sublimation, tissue sections were thawed in a desiccator for ~30 minutes under reduced 
pressure (SpeedVac, Eppendorf, Hamburg, Germany). For teaching of the navigation points 
in Flex Imaging v3.0 software, we used a glass cutter pen (Starwalker, Montblanc, Germany) 
to leave sharp-edged cross signs on tissue-mounted indium tin oxide (ITO) glass. The sections 
were scanned in a slide scanner (PathScan Enabler IV, Electron Microscopy Sciences, 
Hatﬁeld, PA, USA) to visualize the specific brain regions. Matrix deposition for lipid analysis 
was carried out using a vacuum sublimation apparatus (Sigma-Aldrich) comprising an inner 
flat top and an outer bottom attached to each other by an O-ring-sealed flange. The chamber 
was connected to a rough pump attached to a digital vacuum gauge controller and placed in a 
heated sand bath (SiO2, 50−70 mesh particle size, Sigma-Aldrich) on a hot plate (C-MAG HP 
4, IKA Werke GmbH & Co. KG, Staufen, Germany) connected to an electronic contact 
thermometer (ETS-D5, IKA Werke GmbH & Co. KG, Staufen, Germany). Sublimation was 
performed by the following steps. First, vacuum-dried (~20 minutes) ITO-glass slides with the 
thaw-mounted mouse brain tissues were attached to the flat top of the chamber using double-
sided heat conductive copper tape (12mmx16.5m copper, 3M, United States). Then, ~300 mg 
of 1,5-diamnionapthalene (1,5-DAN) matrix powder was spread evenly on the outer bottom of 
the sublimation chamber, which was then attached to the top using the O-ring seal. A vacuum 
of 0.8 mbar was provided by a membrane pump and the system was allowed to equilibrate 
under vacuum for a period of ~20 minutes. The cooler was filled with ice slush (≥0 °C) for 
condensation of the matrix on the sample slides. The process was halted by removing the 
sublimation apparatus from the sand bath and closing the vacuum valve. The sublimation 
apparatus was allowed to slowly re-equilibrate to atmospheric pressure before removal of the 
sample plate. The amount of deposited matrix on ITO glass was determined using a high-
precision scale (AX224, Sartorius, Göttingen, Germany) weighing the amount before and after 
the sublimation experiments. The sublimation protocol was optimized with respect to 
temperature, deposition time and total amount of deposited matrix to obtain the best detection 
efficiency for lipids on mouse brain tissue. With this setup, the optimum matrix layer was found 
to be 120µg/cm2 to give the best lipid signals. We used optimized sublimation conditions: 20 
minutes at a temperature of 130°C under a stable vacuum of 0.8 mbar. Prior to protein analysis, 
tissue sections were washed 2x 100% ethanol (EtOH) (30s) to get rid of the remaining 1,5-
DAN matrix molecules on the tissue surface. Lipids and salts on the tissue surface were 
washed away in sequential washes of 70% EtOH (30s), 100% EtOH (30s), Carnoy’s fluid (6:3:1 
EtOH:chloroform:acetic acid) (2min), 100% EtOH (30s), H2O with 0.2% TFA (30s), and 100% 
EtOH (30s).34 For teaching of the navigation points we used the same sharped-edged cross 
points created with the glass cutter pen prior to lipid analysis to minimize the repositioning error 
between lipid and protein imaging analysis. For protein MALDI-IMS, 2,5-
dihydroxyacetophenone (2,5-DHA) matrix compound was applied using a TM Sprayer (HTX 
Technologies, Carrboro, NC, USA) combined with a HPLC pump (Dionex P-580, Sunnyvale, 
CA, USA). Before every spraying experiment, the corresponding pump valve was cleaned from 
big bubbles using a syringe and ~10 minutes purge was applied to get rid of the little bubbles. 
Then the pump was kept running at 100µl/min using a 70% ACN pushing solvent with isocratic 
pressure for 3 hours. 15mg/ml 2,5-DHA in 60% ACN/1%CH3COOH/1%TFA solution was 
sprayed over the tissue sections using instrumental parameters including nitrogen flow of 10 
psi, spray temperature of 75°C, nozzle height of 40mm, 8 passes with offsets and rotations, a 
spray velocity of 1300 mm/min. These parameters were optimized to avoid analyte 
delocalization on the tissue surface, while keeping the optimum incorporation of matrix and 
analyte molecules for an efficient desorption/ionization. 
MALDI-IMS Analysis. Imaging MS analysis of tissue sections was performed on a MALDI- 
TOF/TOF UltrafleXtreme mass spectrometer equipped with SmartBeam II Nd:YAG/355 nm 
laser operating at 1 kHz providing a laser spot diameter down to ~10µm for the ‘minimum’ 
focus setting (Bruker Daltonics). Measuring the absolute laser pulse energy of a smartbeam II 
laser is challenging in UltrafleXtreme systems, as such a measurement would require a 
reference measurement inside the instrument, which would require modification of the 
instrument hardware. Moreover, SmartBeam lasers do not have a flat-top shaped beam energy 
profile, but a rather highly structured beam energy profile, which makes it a hard task to 
measure the exact value of laser fluence at a flat target surface.35 Therefore, rather than 
measuring the laser pulse energy, we provide detailed information about the laser pulse energy 
settings as previously indicated for lipid analysis in our previous communication;30 global laser 
attenuator setting was kept stable at 10% throughout all the experiments and the laser focus 
set to minimum for 10µm and small for 30µm spatial resolution analysis. Attenuator offset and 
attenuator range settings were 40% and 10% for all the analysis. As SmartBeam II lasers lose 
some energy output over lifetime, it is necessary to specify the laser shot count of the 
instrument unit used for this experimentation, which was about 225696k (in ~12 months age).  
For dual polarity lipid analysis, profiling and imaging data acquisitions were performed in 
reflective ion mode under optimized delayed extraction conditions in a mass range of 300-3000 
Da. First, IMS data acquired with 5 laser shots/per pixel point with a source accelerating 
voltage of 20kV in negative polarity which was followed by 50 laser shots/pixel p 
oint in positive polarity with a source accelerating voltage of 25kV. The detector gain value was 
kept stable at 2626 V for both ionization modes. A mass resolution of M/ΔM 20 000 was 
achieved in the mass window of lipids (i.e., 650−1000 Da). External calibration was carried out 
using peptide calibration standard I (Bruker Daltonics). Image data were reconstructed and 
visualized using Flex Imaging v3.0 (Bruker Daltonics).  
For peptide/protein analysis on the same imaging region of the same tissue section, global 
laser attenuator was increased to 35% while keeping attenuator offset and range settings the 
same. Profiling and imaging data acquisitions were performed in linear positive ion mode in a 
mass range of 2000-20000 Da. Approximately 50 laser shots/raster spot were acquired with 1 
kHz repetition rate.  
Identification of amyloid β plaque-associated lipids and Aβ1-40 m/z 4257.6 was achieved by 
examining MS/MS spectra obtained in LIFT-TOF/TOF mode as previously described.29,31 
MALDI-LIFT (MS/MS) spectra were collected directly from plaque deposits in LIFT mode until 
a satisfactory convolution of fragment spectra was achieved. Lipid classifications were 
determined by comparing mass accuracy data and fragment spectra with the LIPID MAPS 
database (Nature Lipidomics Gateway, www.lipidmaps.org) and previous results obtained on 
tgArcSwe brain tissue sections for the lipid species have already been reported.29,31 
 
RESULTS AND DISCUSSION 
High-Resolution, Dual Polarity MALDI-IMS: Enhanced Hippocampal Lipid Spectral 
Quality and Spatial Molecular Information  
High resolution MALDI-IMS is a strong approach to interrogate the spatial distribution profiles 
of biological molecules associated with spatially-confined histopathological features in 
neuroscience.30,34,36 1,5-DAN was previously demonstrated to be a highly efficient MALDI 
matrix via sublimation matrix coating for brain lipids in both negative and positive polarities 
compared to several commonly used matrix compounds.36 It is also reported that 1,5-DAN 
gives enhanced spectral quality of brain lipid species in a wide spectral range with few number 
of low-energy laser pulses at high spatial resolutions.30 Furthermore, ion signals are distinctly 
diverse and intense in negative polarity compared to positive polarity30,36 which can be 
attributed to distinct reductive properties and radical ion transfer abilities of 1,5-DAN37 With 
respect to enhanced correlated lipidome analysis using 1,5-DAN sublimation MALDI-IMS 
approach, it was also demonstrated that dual polarity lipid analysis can be performed on the 
same pixel points at high spatial resolutions.31 Here, this approach was utilized to reveal a 
comprehensive lipidome of hippocampus region of tgArcSwe mice brain (Figure 1). Due to the 
limitations of the speed of data acquisition in UltrafleXtreme MALDI-TOF/TOF instruments at 
high spatial resolutions which is restricted by the vacuum stability of 1,5-DAN matrix 
molecule36, experiments were performed on the hippocampal areas of tgArcSwe coronal brain 
tissue sections where extensive amyloid plaque aggregates were revealed by previous 
amyloid specific IHC staining and/or MALDI-IMS studies.29,33,38 Enhanced ionization at high-
spatial resolutions using low-energy few number of laser shots along with the minimized matrix-
derived signals revealed a high throughput hippocampal lipid spectral quality in transgenic AD 
mice (tgArcSwe) brain tissue in both polarities and on the same pixel points (Figure1).  
In negative ionization mode, matrix related signals were minimized down to 320 Da. This 
yielded an enhanced low-molecular weight lipid signals (320-620 Da) otherwise would be 
suppressed and/or interfered by matrix-derived signals30, along with the lipids in phospholipid 
range (620-1000 Da) and relatively high-molecular weight species, gangliosides (1000-2000 
Da) (Figure 1Ia). Therefore, this yielded spatially well-resolved, lipid signals in a wide spectral 
range as indicated as ion images of various lipid species such as lysophosphatidic acids (LPA, 
m/z 409.3), ceramides (Cer 18:0 m/z 564.6), ceramide phosphates (Cer P, m/z 644.6), 
phosphatidylethanolamines (PE 40:6, m/z 790.6), phosphatidylinositols (PI 38:4, 885.6), 
sulfatides (ST 24:0, 888.6) and gangliosides (GM3 18:0, m/z 1179.7, GM1 18:0, m/z 1544.8) 
(Figure 1Ib). In positive ion mode, matrix related signals were minimized down to 420 Da. This 
allowed us to observe low-molecular weight lysophosphatidylcholines, otherwise would be 
suppressed and/or interfered by matrix-derived signals30 (Figure 1IIa).  Moreover, intense 
phospholipid signals, mainly phosphatidylcholines, were observed in the mass range of 650-
900 Da along with the dimer peaks of phospholipids (1400-1700 Da) as previously observed 
in MALDI-TOF-MS39 (Figure 1IIa). As a result, spatially well-resolved ion images of 
lysophophatidycholines (LPC 16:0, m/z 496.3, LPC 18:1, m/z 522.3, LPC 18:0, m/z 524.3, LPC 
20:4, m/z 544.3) and phosphatidycholines (PC 32:0, m/z 734.6, PC 34:1, m/z 760.6, PC 36:4, 
m/z 782.6, PC 38:6, m/z  806.6) were observed (Figure 1IIb), which can be simultaneously 
correlated with ion images obtained in negative polarity on the same pixel points (Figure 1Ib). 
 
 Figure 1. MALDI-MS spectra acquired subsequently in I a) negative and II a) positive ion mode on the 
same pixel points from hippocampal region of a coronal tissue section of tgArcSwe mouse brain. I a) 
Inset spectra in negative ion mode from left to right indicates low molecular weight (320-620 Da) lipid 
I
II
species and relatively high-molecular weight (1000-2000) lipid species, respectively. I b) Ion images of 
lipid species such as lysophosphatidic acids (LPA, m/z 409.3), ceramides (Cer 18:0 m/z 564.6, Cer P, 
m/z 644.6), phosphatidylethanolamines (PE 40:6, m/z 790.6), phosphatidylinositols (PI 38:4, 885.6), 
sulfatides (ST 24:0, 888.6) and gangliosides (GM3 18:0, m/z 1179.7, GM1 18:0, m/z 1544.8). II a) Inset 
spectra in positive ion mode from left to right indicates low molecular weight (420-620 Da) lipid species 
and relatively high-molecular weight (1400-1700) phospholipid dimers, respectively. II b) Ion images of 
lipid species such as lysophosphatidylcholines (LPC 16:0, m/z 496.3, LPC 18:1, m/z 522.3, LPC 18:0, 
m/z 524.3, LPC 20:4, m/z 544.3) and phosphatidycholines (PC 32:0, m/z 734.6, PC 34:1, m/z 760.6, PC 
36:4, m/z 782.6, PC 38:6, m/z 806.6). 
 
On the other hand, enhanced ionization of lipid species at high-spatial resolutions allowed us 
to observe pathological lipid changes not only brain region-specific but also directly correlated 
to the plaque aggregates (Figure 2), whose amyloid β identities were demonstrated by 
subsequent peptide imaging on the same imaging sequence in hippocampus of tgArcSwe 
(Figure 3). To further demonstrate the relevance of high-resolution to probe plaque-associated 
lipid changes, we compared ion images obtained at 30μm and 10μm spatial resolutions in 
equivalent hippocampal regions of subsequent tissue sections (Figure 2). For example, ion 
images of ceramide phosphates (CerP 18:0, 644.6), phosphatidylethanolamines (PE 40:6, m/z 
790.6), and phosphatidylinositols (PI 38:4, m/z 885.6) display distinct amyloid-plaque 
associated localizations which can be observed explicitly at a spatial resolution of 10 μm 
(Figure 2b) but not with 30μm (Figure 2a). In detail, accumulation of CerP 18:0 and PI 38:4 in 
the cores and periphery of certain amyloid plaques, respectively, along with the mild reduction 
of PE 40:6 in the certain amyloid plaques in spatially well-resolved hippocampal regions can 
be luculently observed at 10μm spatial resolutions (Figure 2b).  
 Figure 2. MALDI-IMS analysis of tgArcSwe mice hippocampal lipids of coronal mouse brain tissue 
section. Ion images of Ceramide phosphates (CerP 18:0, m/z 644.6), phosphatidylethanolamines (PE 
40:6, m/z 790.6), phosphatidylinositols (PI 38:4, 885.6) were obtained in negative ion mode at spatial 
resolutions of a) 30 μm b) 10 μm. Scale bars: 2 mm. 
Amyloid Plaque Identification by Subsequent High-resolution Peptide MALDI-IMS on the 
Same Tissue Section 
1,5-DAN via sublimation allows enhanced ionization of lipid species without the need of high 
laser pulse energies.30 This ‘’gentle’’ MALDI-IMS methodology preserves the tissue 
morphology by minimizing the thermal and mechanical nanosecond laser ablation effects 
during the laser desorption/ionization process30 and therefore allows successful fluorescent 
immunohistochemistry30 or peptide/protein MALDI-IMS31 on the same tissue section. In order 
to demonstrate the amyloid identity of lipid aggregates in the same hippocampal regions, 
subsequent MALDI-IMS was applied for peptide/protein analysis on the same tissue section.  
This approach was demonstrated to be an alternative and superior strategy to previously 
applied amyloid specific immunohistochemistry and fluorescent staining experiments as it 
allows correlation of multiple Aβ isoform ion images with lipid ion images in dual polarity.31 
Therefore, we employed tri-modal MALDI-IMS paradigm for negative- and positive ion mode 
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lipid analysis and subsequent peptide/protein ion imaging on the same tissue section at 30μm 
and 10μm spatial resolutions (Figure 3). High spatial resolution (10μm) tri-modal MALDI-IMS 
revealed an accurate correlation of dual polarity lipid ion images such as phosphatidylinositols 
(PI 38:4, 885.6) in negative ion mode and lysophosphatidylcholines (LPC 16:0, m/z 496.3) in 
positive ion mode with the ion image of amyloid peptide Aβ 1-40 (Figure 4b) to individual 
plaques, whereas the correlation was not conclusive at 30μm spatial resolution (Figure 3a). 
These results are potentially important as this high spatial resolution method allows correlation 
of tri-modal ion images to not only brain regions but also to individual plaque features which 
are spatially well-resolved (Figure 3b). 
 
Figure 3. Trimodal MALDI-IMS analysis of tgArcSwe mice hippocampal lipids and peptides on the 
same tissue section. Ion images of phosphatidylinositols (PI 38:4, m/z 885.6) in reflective negative ion 
mode, lysophosphatidylcholines (LPC 16:0, m/z 496.3) in reflective positive ion mode and amyloid 
peptide (Aβ 1-40, m/z 4257.6)  in linear positive ion mode  were obtained  at a) 30μm and b) 10μm 
spatial resolutions. Scale bars: 2 mm. 
All in all, these methodologies suggest a high throughput investigation of lipid 
microenvironment of individual Aβ plaques and elucidate their plaque-associated alterations.  
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Amyloid Plaque-Associated Alterations of Lipids in tgArcSwe Mice Brain Revealed by 
Multimodal MALDI-IMS: Insights into the Molecular Pathology  
Amyloid plaque formation is a dynamic process which was regulated by several enigmatic 
biochemical and biophysical processes. Most of the lipid classes were shown to be crucial  
players in AD pathogenesis including amyloid plaque pathology.8,15 Based on the published 
studies, one could have in view following main mechanisms for the action of lipids in amyloid 
pathology and senile plaque formation: Firstly, the interaction of amyloid peptides and/or 
amyloid oligomers with the cellular membranes effecting the membrane lipid homeostasis 
and/or effecting the organization and physicochemical properties of  the membrane bilayer 
which alters APP processing.11,40 Secondly, the functional roles of peptides/proteins such as 
Aβ and APP Intracellular domain (AICD) in the regulation of lipid metabolism pathways either 
directly or by effecting the gene expressions encoding for APP, BACE1, the Aβ-degrading 
protease neriplysin (NEP) as well as several enzymes involved in lipid metabolism.15,41-45 
Bidirectionally, lipid-peptide/protein interactions, whereby changes in lipids modulate the 
function of target proteins such as APP and APP-cleaving secretases.46,47 Finally, catalyzer  
and/or interfacial role of lipids in amyloid oligomerization and fibrillization.12,48,49 Considering 
the heterogeneity of lipid molecules and complex bidirectional link between lipids and amyloid 
pathology, it is expectative to observe amyloid plaque-associated alterations of several lipid 
classes in tgArcSwe mice brain tissue. Here, high-resolution, highthroughput MALDI-IMS 
reveals a number of amyloid plaque-associated alterations of lipids including sphingolipids, 
phospholipids and lysophospholipids, which can give insights in to the molecular pathology of 
AD pathogenesis. 
Sphingolipids including ceramides, sphingomyelins, and glycosphingolipids (GSLs) are major 
components of lipid rafts, playing a number of crucial parts in cell functions.50 Growing 
evidence indicating that the amyloidogenic processing of APP occurs in lipid rafts9 closely links 
sphingolipids to amyloid pathology. Moreover, the APP-processing product AICD 
downregulates the gene expression encoding for serine palmitoyl-CoA (SPT) enzyme which 
initiates the sphingolipid biosynthesis.42 In addition, a number of studies have been reported 
on the alterations of sphingolipids in post-mortem human AD and transgenic AD mice brain 
tissue and their potential to modulate APP processing and Aβ aggregation.51,52  
High-spatial resolution MALDI-IMS was performed on a hippocampal and adjacent cortical 
regions of a coronal tgArcSwe mice brain tissue section (Figure 4). Inspection of ion images in 
reflective negative ion mode revealed plaque-associated alterations of sphingolipids such as 
the accumulation of ceramides (Cer 14:0 m/z 508.3, Cer 18:0 m/z 564.6), and gangliosides 
(GM3 18:0, m/z 1179.8, GM3 20:0, m/z 1207.8, GM2 18:0, m/z 1382.8 ) along with the 
depletion of sulfatides (ST 18:0, m/z 806.8, ST 22:0, m/z 862.8, ST 22:0(OH), m/z 878.8, ST 
24:0, m/z 890.8, ST 24:0 (OH), 906.8 m/z). Further, subsequent MALDI-IMS for peptides was 
performed on the same region of the tissue section to identify the amyloid deposits. An intense 
accumulation of Aβ 1-40, m/z 4257.6 (Figure 4m) along with the other amyloid isoforms (Aβ 1-
37, m/z 4002.7, Aβ 1-38, m/z 4060.3 and Aβ 1-42 m/z 4441.2) (Figure 4p) all colocalized with 
spatial lipid alterations. 
Amyloid plaque-associated alterations of certain sphingolipids were previously described for 
the same transgenic mice (tgArcSwe) using MALDI-IMS and subsequent IHC and fluorescent 
staining on the same tissue section.29 Here, high spatial-resolution multimodal MALDI-IMS 
reveals amyloid-plaque associaited alterations of several sphingolipid species all correlated to 
multiple Aβ isoforms at 10µm spatial resolution (Figure 4). Previously, shotgun lipidomics 
consistently revealed substantial decrease of sufatides and large content increase of 
ceramides in post-mortem human AD brain extracts relative to cognitively normal age-matched 
controls.18 Our data indicates both hydroxylated and non-hydroxylated sulfatides, irrespective 
of their fatty acid (FA) moeity, depletes on the amyloid plaques (Figure 4e-i). Interestingly, ST 
(18:0) species shows lesser depletion relative to the longer chain sulfatides in the center of the 
plaques and a clear elevation on the vicinity (Figure 4e).  
 Figure 4. Amyloid plaque-associated alterations of sphingolipids correlated with amyloid peptide 
isoforms revealed by Multimodal MALDI-IMS on the same tissue section of tgArcSwe mouse brain.a) 
brightfield image of coronal brain tissue section of tgArcSwe b) Cer 14:0, m/z 508.3, c) Cer 18:0, m/z 
564.6, d) Cer P 18:0, m/z 644.6, e) ST18:0, m/z 806.8, f) ST 22:0, m/z 862.8, g) ST:22:0 (OH), m/z 
878.8, h) ST 24:0, m/z 890.8, i) ST 24:0 (OH), m/z 906.8, j) GM3 18:0, m/z 1179.8, k) GM3 20:0, m/z 
1207.8, l) GM2 18:0, m/z 1382.8 m) Aβ 1-40, m/z 4257.6, n) merged  ion images of sulfatides (green) 
and ceramides (red), o) merged ion images of sulfatides(red) and gangliosides (green), p) merged ion 
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ST (18:0)
ST (24:0 (OH) )
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images of sulfatide(green) and amyloid peptides isoforms (blue) (Aβ 1-37, m/z 4002.7, Aβ 1-38, m/z 
4060.3 and Aβ 1-42, m/z 4441.2). Scale bar: 2mm. 
 
Further, elevation of ceramides (Cer 14:0, Cer 18:0) were correlated with the depletion of all 
the sulfatides (Figure 4n) and all together correlated to amyloid isoforms (Figure 4m, 4p). On 
the other hand, ceramide phosphates (CerP 18:0, m/z 644.6) showed an inconsistent plaque-
associated distribution. They were elevated in the cores and depleted on the edges of certain 
plaques (Figure 2b, Figure 4d), which might be attributed to the structural heterogeneity and 
therefore the distinct molecular composition of amyloid plaques. 
Sulfatides are one of the main consitutents of the myelin sheath surrounding axons in the CNS 
and mainly synthesized by oligodendrocytes playing key roles in the regulation of 
oligodendrocyte maturation and myelin formation.53,54 Ceramides are the central components 
in sphingolipid metabolism and serve as the backbones to generate sphingomyelin (SM) and 
GSLs including sulfatides and gangliosides. Early reports indicated the role of apoE in both 
CNS and peripheral nervous system which is the regulation of sulfatide level.55 Further, it has 
been hypothesized that the alterations of APOE ε4 allele-associated sphingolipid homeostasis 
through lipoprotein pathways can lead the depletion of sulfatides in myelin sheaths.56,57 On the 
other hand, the ceramide elevation in AD was suggested to be a possible degradation product 
of sulfatides18, but other explanations include Aβ induced membrane oxidative stress58, Aβ-
mediated activation of sphingomyelinases (SMases) catalyzing the breakdown of SM to 
ceramide59,60, and multiple gene expression abnormalities such as increased cerebral 
expression of genes involved in ceramide de novo synthesis along with the reduced expression 
of genes reguired for glycosphingolipid synthesis out of ceramide.61 Our data suggest both 
sulfatide depletion and ceramide elevation are amyloid plaque-associated phenomena in 
tgArcSwe AD mice pathology (Figure 4m,n,p). Indeed, an earlier study performed by 
quantitative fluorescent staining revealed amyloid plaque-associated demyelination and 
oligodendrocyte loss in both human and transgenic mice AD-brain.62 Therefore, substantial 
amyloid plaque-associated depletion of sulfatides could reinforce the the previous results 
indicating amyloid plaques could be associated with regression of myelination which is another 
pathological hallmark AD.                                                                                                                                   
Along with sulfatide depletion and ceramide elevation, substantial accumulation of 
gangliosides (GM3 18:0, GM3 20:0, GM2 18:0) were revealed on the same amyloid plaques 
(Figure 4j-l, o). Most earlier studies indicated a general reduction of gangliosides63-65 along with 
the elevation of simpler gangliosides (GM2, GM3)65,66 in both transgenic mice and human AD 
brain extracts, which was hypothesized to be a result of accelerated lysosomal degradation 
and/or astrogliosis during neuronal cell death.66 This in line with the reported accumulations of 
GM2 and GM3 in lysosomal storage disorders.67,68  
Phospholipids are essential constituents of neuronal membranes providing structural integrity 
and functional properties.69 Moreover, lysophospholipids, metabolic intermediates of 
phospholipid metabolism70 interact with the lipid and protein moieties of neural membranes 
and modulate the function of neural membrane proteins, such as enzymes and growth 
factors.71 Along with the sphingolipids, alterations in the levels of phospholipids, 
lysophospholipids along with the phospholipid-metabolizing enzymes such as PLA2, PLC, and 
PLD were reported in post-mortem human and trangenic AD mice brain tissues.72-75 
Despite the high abundance and the efficient ionization of many of them, the structural diversity 
of phospholipids and lysophospholipids limit their comprehensive screening within a single 
MALDI-IMS analysis. Therefore, subsequent dual polarity lipid MALDI-IMS on the same tissue 
section increases the number of detected lipid species which can be correlated to spatial 
histopathological features.31,36,76 Here, high spatial resolution, dual polarity analysis on the 
hippocampus of tgArcSwe mice brain tissue allowed us to simultaneously correlate the 
alterations of phospholipid (Figure 5) and lysophospholipid (Figure 6) species to microscopic 
amyloid plaque structures. In detail, lysophosphatidic acids (LPA), phosphatidic acids (PA), 
lysophosphatidylethanolamine (LPE), phosphatidylethanolamines (PE), phosphatidylserines 
(PS), lysophosphatidylinositols (LPI) and phosphatidylinositols (PI)  are observed in negative 
ion mode can be correlated lysophosphatidylcholines (LPC) and phosphatidylcholines (PC) 
which are observed in positive ion mode on the same pixel points. (Figure 5,6) Inspection of 
ion images in phsopholipid region revealed depletion of PE (40:6 m/z 790.6), PE-p (40:6 m/z 
774.6), PS (40:6 m/z 834.6) species along with the elevation of PA (32:0, m/z 647.5), PE-
NMe2 (32:0 m/z 718.5), PC (32:0 m/z 734.6), PE (36:1 744.5), PI (36:4 m/z 857.6), PI (38:5 
m/z 883.6), PI (38:4 m/z 885.6) species on the amyloid plaque regions (Figure 5). Interestingly, 
PA (34:2 m/z 671.5) species revealed inconsistent distributions. Heteregoneous elevation and 
depletion of them were observed on the amyloid plaque regions (Figure 5c). 
 
Figure 5. Amyloid plaque-associated alterations of phospholipids including phosphatidic acids (PA), 
phosphatidylethanolamines (PE), phosphatidylcholines (PC), phosphatidylserines (PS) and 
phosphatidylinositols (PI) were revealed by dual polarity MALDI-IMS on the same pixel points. a) 
brightfield image of coronal brain tissue section of tgArcSwe, b) PA (32:0, m/z 647.5), c) PA (34:2 m/z 
671.5), d) PE-NMe2 (32:0 m/z 718.5 ), e) PC (32:0 m/z 734.6), f) PE (36:1 744.5), g) PE (40:6 m/z 
790.6), h) PE-p (40:6 m/z 774.6), i) PS (40:6 m/z 834.6), j) PI (36:4 m/z 857.6), k) PI (38:5 m/z 883.6) 
and l) PI (38:4 m/z 885.6). Scale bar: 2 mm.    
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Early reports generally indicated reductions of PE-PLs, PC-PLs and PI-PLs in human post-
mortem and transgenic AD-brains17,72,77,78 which was speculated to be due to the increased 
oxidative stress and stimulated activity of phospholipases in the presence of Aβ peptides 
resulting in PL degradation.75,79,80 Our data indicates a clear depletion of phospholipids 
containing polyunsaturated fatty acids (PUFA) in their structure including PE (40:6 m/z 790.6), 
PE-p (40:6 m/z 774.6), PS (40:6 m/z 834.6) on the amyloid plaques which might be a result of 
lipid peroxidation by amyloid plaque-associated oxidative stress as previously demonstrated.80-
82 On the other hand, PA (32:0, m/z 647.5), PE-NMe2 (32:0 m/z 718.5), PC (32:0 m/z 734.6), 
PE (36:1 744.5) species containing no or few unsaturated fatty acids in their structure were 
elevated on amyloid plaques which can be explained by the possible binding of these lipids to 
amyloid peptides during amyloid oligomerization.83 In contrast to earlier reports on brain tissue 
extracts72, phosphatidylinositol including PI (36:4 m/z 857.6), PI (38:5 m/z 883.6), PI (38:4 m/z 
885.6) were elevated and localized to amyloid plaques, irrespective of their FA moeity (Figure 
5j,k,l). While this can be due to the pathogenesis difference between human and transgenic 
mice AD-brains, our results represents the alterations of this species in spatially confined 
amyloid plaques. AD-associated reduction of phosphatidylinositol kinase activity and depletion 
of phosphoinositide species in human AD-brain tissue were previously reported.72,84 
Furthermore, oligomeric Aβ peptide was demonstrated to hinder phosphatidylinositol-4,5-
biphosphate levels in neurons.11 Therefore, elevation of phosphatidylinositols on amyloid 
plaques might be associated with disruption of phosphoinositide formation pathways. 
Along with the amyloid plaque-associated alterations of phospholipids, inspection of ion 
images revealed accumulation of lysophospholipids including LPA (16:0, m/z 409.3), LPA 
(18:1, m/z 435.3), LPA (18:0, m/z 437.3), ) LPE (16:0, m/z 452.5), LPE (18:0, m/z 480.5), LPC 
(16:0, m/z 496.3), ) LPC (18:1, m/z 522.3), LPC (18:0, 524.3) to amyloid plaques. (Figure 6) 
Elevation of LPC species were previously demonstrated in the brains of 9 month-old transgenic 
AD mice (5XFAD) using MALDI-IMS.75 Further, immunostaining of amyloid peptides and PLA2 
indicated an extensive accumulation of amyloid peoptides in the cortex and subiculum along 
with the partial accumulation of PLA2 around the Aβ plaques.75 Therefore, this suggest an 
amyloid plaque-associated hyperactivity of PLA2  which can result in the accumulation of 
lysophospholipids.85 Our high spatial resolution reveals that lysophospholipid accumulation is 
amyloid plaque-associated phenomenon in tgArcSwe AD mice pathology which might be 
explained by the stimulated activity of phospholipases around amyloid plaques. 
 
Figure 6. Amyloid plaque-associated alterations of lysophospholipids including lysophosphatidic acids 
(LPA), lysophoshatidylethanolamines (LPE), lysophosphatidylcholines (LPC) and 
lysophosphatidyinositols (LPI) were revealed by dual polarity MALDI-IMS on the same pixel points. a) 
brighfield image of the coronal brain tissue section of tgArcSwe. b) LPA (16:0, m/z 409.3), c) LPA( 18:1, 
m/z 435.3), d) LPA (18:0, m/z 437.3), e) LPE (16:0, m/z 452.5), f) LPE (18:0, m/z 480.5), g) LPC (16:0, 
m/z 496.3), h) LPC (18:1 m/z 522.3), i) LPC (18:0 524.3), j) LPC (20:4, m/z 544.3), k) LPI (16:0, 571.3), 
l) LPI (18:0, m/z 599.3). Scale bar: 2mm 
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In summary, we have applied a multimodal MALDI-IMS method to reveal highthroughput 
molecular information on amyloid plaques at high spatial resolutions in 18 month-old 
transgenic (tgArcSwe) AD mouse brains. Inspection of ion images revealed  plaque-associated 
accumulation of amyloid peptides isoforms and neuronal lipids at high spatial resolutions. Dual 
polarity MALDI-IMS analysis of lipids revealed high troughput lipid molecular information which 
can be correlated to individual amyloid plaques at 10um spatial resolution. Here, we were, for 
the first time, able to correlate amyloid plaque-associate alterations of several sphingolipids, 
phospholipids and lysophospholipids to individual plaque features and certain amyloid peptide 
isoforms on the same tissue section. In conclusion, this methodology substantially increased 
the spatial amyloid plaque-associated molecular information. Insights into the possible 
pathways for the plaque-associated alterations of lipids were discussed. 
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